HPV-positive women with normal cytology remain at increased risk of CIN3 after a negative repeat HPV test

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Background:In human papillomavirus (HPV)-based screening, a repeat HPV test is often recommended for HPV-positive women with normal cytology (HPV-pos/cyt-neg), but its absolute risk of cervical precancer (CIN3+) over two screening rounds needs to be assessed.Methods:We compared the 5-year risk of HPV infection and CIN3+ in HPV-pos/cyt-neg women with a negative repeat HPV test to the risk in HPV-negative women with normal cytology (double negatives) in the POBASCAM cohort. We obtained histology data from the Dutch pathology registry (PALGA).Results:Human papillomavirus infection risk was 20.4% (19 of 93) in HPV-pos/cyt-neg, repeat HPV-negative women and 3.2% (294 of 9186; P<0.001) in double negatives. Corresponding CIN3+ risks were 2.0% (4 of 199) and 0.2% (41 of 18 562; P<0.001). Infection risks were also increased in type-specific analyses of HPV16, 31, 33, 39, 52, 56 and 58.Conclusions:HPV-pos/cyt-neg women continue to have an increased CIN3+ risk, also when the repeat HPV test is negative. Therefore, intervals in primary HPV screening should be determined separately for HPV-positive and -negative women.

Original languageEnglish
Pages (from-to)1557-1561
Number of pages5
JournalBritish Journal of Cancer
Volume117
Issue number10
DOIs
Publication statusPublished - 7 Nov 2017

Cite this

@article{5e4683942ea14b13b15c85a7abd4be43,
title = "HPV-positive women with normal cytology remain at increased risk of CIN3 after a negative repeat HPV test",
abstract = "Background:In human papillomavirus (HPV)-based screening, a repeat HPV test is often recommended for HPV-positive women with normal cytology (HPV-pos/cyt-neg), but its absolute risk of cervical precancer (CIN3+) over two screening rounds needs to be assessed.Methods:We compared the 5-year risk of HPV infection and CIN3+ in HPV-pos/cyt-neg women with a negative repeat HPV test to the risk in HPV-negative women with normal cytology (double negatives) in the POBASCAM cohort. We obtained histology data from the Dutch pathology registry (PALGA).Results:Human papillomavirus infection risk was 20.4{\%} (19 of 93) in HPV-pos/cyt-neg, repeat HPV-negative women and 3.2{\%} (294 of 9186; P<0.001) in double negatives. Corresponding CIN3+ risks were 2.0{\%} (4 of 199) and 0.2{\%} (41 of 18 562; P<0.001). Infection risks were also increased in type-specific analyses of HPV16, 31, 33, 39, 52, 56 and 58.Conclusions:HPV-pos/cyt-neg women continue to have an increased CIN3+ risk, also when the repeat HPV test is negative. Therefore, intervals in primary HPV screening should be determined separately for HPV-positive and -negative women.",
author = "Polman, {Nicole J.} and Veldhuijzen, {Nienke J.} and Heideman, {Dani{\"e}lle A.M.} and Snijders, {Peter J.F.} and Meijer, {Chris J.L.M.} and Johannes Berkhof",
year = "2017",
month = "11",
day = "7",
doi = "10.1038/bjc.2017.309",
language = "English",
volume = "117",
pages = "1557--1561",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "10",

}

HPV-positive women with normal cytology remain at increased risk of CIN3 after a negative repeat HPV test. / Polman, Nicole J.; Veldhuijzen, Nienke J.; Heideman, Daniëlle A.M.; Snijders, Peter J.F.; Meijer, Chris J.L.M.; Berkhof, Johannes.

In: British Journal of Cancer, Vol. 117, No. 10, 07.11.2017, p. 1557-1561.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - HPV-positive women with normal cytology remain at increased risk of CIN3 after a negative repeat HPV test

AU - Polman, Nicole J.

AU - Veldhuijzen, Nienke J.

AU - Heideman, Daniëlle A.M.

AU - Snijders, Peter J.F.

AU - Meijer, Chris J.L.M.

AU - Berkhof, Johannes

PY - 2017/11/7

Y1 - 2017/11/7

N2 - Background:In human papillomavirus (HPV)-based screening, a repeat HPV test is often recommended for HPV-positive women with normal cytology (HPV-pos/cyt-neg), but its absolute risk of cervical precancer (CIN3+) over two screening rounds needs to be assessed.Methods:We compared the 5-year risk of HPV infection and CIN3+ in HPV-pos/cyt-neg women with a negative repeat HPV test to the risk in HPV-negative women with normal cytology (double negatives) in the POBASCAM cohort. We obtained histology data from the Dutch pathology registry (PALGA).Results:Human papillomavirus infection risk was 20.4% (19 of 93) in HPV-pos/cyt-neg, repeat HPV-negative women and 3.2% (294 of 9186; P<0.001) in double negatives. Corresponding CIN3+ risks were 2.0% (4 of 199) and 0.2% (41 of 18 562; P<0.001). Infection risks were also increased in type-specific analyses of HPV16, 31, 33, 39, 52, 56 and 58.Conclusions:HPV-pos/cyt-neg women continue to have an increased CIN3+ risk, also when the repeat HPV test is negative. Therefore, intervals in primary HPV screening should be determined separately for HPV-positive and -negative women.

AB - Background:In human papillomavirus (HPV)-based screening, a repeat HPV test is often recommended for HPV-positive women with normal cytology (HPV-pos/cyt-neg), but its absolute risk of cervical precancer (CIN3+) over two screening rounds needs to be assessed.Methods:We compared the 5-year risk of HPV infection and CIN3+ in HPV-pos/cyt-neg women with a negative repeat HPV test to the risk in HPV-negative women with normal cytology (double negatives) in the POBASCAM cohort. We obtained histology data from the Dutch pathology registry (PALGA).Results:Human papillomavirus infection risk was 20.4% (19 of 93) in HPV-pos/cyt-neg, repeat HPV-negative women and 3.2% (294 of 9186; P<0.001) in double negatives. Corresponding CIN3+ risks were 2.0% (4 of 199) and 0.2% (41 of 18 562; P<0.001). Infection risks were also increased in type-specific analyses of HPV16, 31, 33, 39, 52, 56 and 58.Conclusions:HPV-pos/cyt-neg women continue to have an increased CIN3+ risk, also when the repeat HPV test is negative. Therefore, intervals in primary HPV screening should be determined separately for HPV-positive and -negative women.

UR - http://www.scopus.com/inward/record.url?scp=85030158122&partnerID=8YFLogxK

U2 - 10.1038/bjc.2017.309

DO - 10.1038/bjc.2017.309

M3 - Article

VL - 117

SP - 1557

EP - 1561

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 10

ER -